Epigenetic & ctDNA Diagnostics
A biological portrait — read with clarity.
Overview
A longitudinal portrait of your biology — epigenetic age, pace of ageing, and circulating tumour DNA — read from a single blood draw and interpreted alongside your full clinical picture.
Advanced epigenetic assays (OMICm Age, DunedinPACE) establish biological age and pace of ageing. Signatera ctDNA screening surveys for early molecular signals of disease.
Read together, they produce a private, longitudinal portrait — the basis for every subsequent decision in the framework.
The Science
Why this works.
- 01
OMICm Age integrates DNA methylation with proteomic and metabolomic markers to produce a composite biological age with unprecedented accuracy.
- 02
DunedinPACE measures your current rate of ageing — how many biological years pass per calendar year — enabling intervention efficacy to be measured in months rather than decades.
- 03
Signatera ctDNA is a bespoke assay that detects circulating tumour DNA at parts-per-million sensitivity, providing early molecular signal often years before conventional screening.
The Process
A protocol conducted without theatre.
01
Single blood draw
All three assays are performed from one visit — approximately 40 ml of blood.
02
Laboratory processing
Samples are shipped to specialist laboratories in the US and Europe; results within four to six weeks.
03
Interpretation session
A ninety-minute private consultation with the medical director to interpret results in context.
04
Framework integration
Findings are woven into your active protocol and re-assessed annually.
05
Longitudinal reporting
Year-on-year trend reports quantify the effect of every intervention undertaken.
Considered for
All members — this is the baseline from which the framework is built.
Members seeking objective measurement of interventions rather than subjective feel.
Those with family history requiring early oncological surveillance.
Outcomes
- →
A quantified biological age and pace of ageing at baseline.
- →
Early molecular signal for oncological surveillance, typically preceding imaging by 12–24 months.
- →
Longitudinal proof that interventions are producing physiological change.
All assays are conducted by internationally accredited laboratories; results remain in your private member record.